{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-009748","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.922881+00:00","generated_at":"2026-06-18T14:11:19.383454+00:00","sec_items":["1.01","2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Catalyst sells rare bleeding disorder assets to GC Biopharma for $6M; GNI revenue $102M","bullets":["Sold MarzAA, DalcA, and CB-2679d-GT to GC Biopharma for $6M total ($1M upfront, $5M holdback due Feb 2025).","Net proceeds from sale to be distributed to holders of contingent value rights issued to stockholders of record Jan 5, 2023.","GNI Group reported FY2022 revenue ~$102M and net profit ~$23M from pirfenidone sales in China for IPF.","GNI Transactions (purchase of F351 assets and controlling interest in Beijing Continent) remain pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-009748","json":"https://secwatch.observer/filing/0001140361-23-009748.json","markdown":"https://secwatch.observer/filing/0001140361-23-009748.md","text":"https://secwatch.observer/filing/0001140361-23-009748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/brhc10049211_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T14:11:19.383454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77cec0d07d2b230f61ba68b8ca1cf064c4e2657e","claim":"GYRE THERAPEUTICS, INC. completed a disposition involving GC Biopharma Corp. for $6 million in cash (closed 2023-02-27).","evidence_excerpt":"(MarzAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the “Purchased Assets”). In consideration for the purchase of the Purchased Assets, Buyer will pay Catalyst a total of $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back until twenty-four months after the closing, subject to the satisfaction of post-closing","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"GC Biopharma Corp."},{"label":"Consideration","value":"$6 million in cash"},{"label":"Closing","value":"2023-02-27"}],"fact_type":"ma_transaction"},{"claim_id":"7431ed48de1283d54932d21d93159ac932698e07","claim":"GYRE THERAPEUTICS, INC. entered into Purchase Agreement with GC Biopharma Corp. valued at $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back (effective 2023-02-27).","evidence_excerpt":"On February 27, 2023, Catalyst Biosciences, Inc. (“Catalyst”) entered into and closed on an Asset Purchase Agreement (the “Purchase Agreement”) with GC Biopharma Corp. (“Buyer”), pursuant to which Buyer acquired on such date Catalyst’s legacy rare bleeding disorder program, including marzeptacog alpha activated (MarZAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the “Purchased Assets”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"GC Biopharma Corp."},{"label":"Value","value":"$6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back"},{"label":"Effective","value":"2023-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}